SecBot SecBot
SECBOTREPLAY Home › Report › CELC

CELC · Celcuity submitted a supplemental New Drug Application (sNDA) to the…

Celcuity Inc. · 8-K filed Aug 26, 2026 at 08:35 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 26, 2026 at 08:35 ET

Celcuity submitted a supplemental New Drug Application (sNDA) to the FDA for REVTORPYK (gedatolisib) to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation. This follows the drug's recent FDA approval on July 14, 2026, for the PIK3CA wild-type population. The sNDA is supported by Phase 3 VIKTORIA-1 data showing a 50% reduction in the risk of disease progression or death versus alpelisib, potentially doubling the drug's addressable patient population.

  • Celcuity submitted an sNDA to the FDA for REVTORPYK (gedatolisib) for HR+/HER2- advanced breast cancer with a PIK3CA mutation.
  • The sNDA is supported by the Phase 3 VIKTORIA-1 trial, which showed the REVTORPYK-triplet reduced the risk of disease progression or death by 50% vs. alpelisib plus fulvestrant (HR=0.50; p<0.0001).
  • Median progression-free survival (PFS) was 11.1 months with the REVTORPYK-triplet vs. 5.6 months with alpelisib plus fulvestrant.
  • REVTORPYK was already approved by the FDA on July 14, 2026, for the PIK3CA wild-type population, and this sNDA seeks to expand the label to include PIK3CA mutant patients.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access